SI
DYN icon

Sofinnova Investments’s Dyne Therapeutics DYN Stock Holding History

Sofinnova Investments’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.6M Sell
1,633,897
-620,264
-28% -$10.7M 1.13% 32
2025
Q4 		$44.1M Buy
2,254,161
+1,268,333
+129% +$24M 1.9% 15
2025
Q3 		$12.5M Buy
985,828
+370,963
+60% +$4.23M 0.68% 40
2025
Q2 		$5.85M Sell
614,865
-102,031
-14% -$1.12M 0.36% 48
2025
Q1 		$7.5M Sell
716,896
-354,602
-33% -$5.07M 0.49% 45
2024
Q4 		$25.2M Buy
1,071,498
+299,428
+39% +$8.86M 1.84% 19
2024
Q3 		$27.7M Sell
772,070
-853,633
-53% -$34M 2.2% 14
2024
Q2 		$57.4M Sell
1,625,703
-310,947
-16% -$9.04M 2.98% 9
2024
Q1 		$55M Buy
1,936,650
+923,145
+91% +$20.9M 3.06% 11
2023
Q4 		$13.5M Buy
1,013,505
+328,372
+48% +$3.21M 0.75% 31
2023
Q3 		$6.14M Buy
685,133
+244,085
+55% +$2.63M 0.39% 44
2023
Q2 		$4.96M Buy
+441,048
New +$5.2M 0.33% 37

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Sofinnova Investments's DYN Position: Q1 2026 in Review

Sofinnova Investments reduced its Dyne Therapeutics (DYN) stake by 28% in Q1 2026, selling an estimated $10.7M and leaving 1,633,897 shares worth $29.6M. The position accounts for 1.13% of the portfolio, ranked #32.

Sofinnova Investments first reported a position in DYN in Q2 2023 and has held it in 12 quarters since. The position peaked at $57.4M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Sofinnova Investments held 1,633,897 shares of Dyne Therapeutics worth $29.6M as of Q1 2026.
  • Sofinnova Investments sold 620,264 Dyne Therapeutics shares in Q1 2026, an estimated $10.7M.
  • Dyne Therapeutics made up 1.13% of Sofinnova Investments's portfolio in Q1 2026, its #32 holding.
  • Sofinnova Investments first reported a position in Dyne Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Sofinnova Investments's Dyne Therapeutics position peaked at $57.4M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.